BL Pharmtech Statistics

Total Valuation

BL Pharmtech has a market cap or net worth of KRW 15.98 billion. The enterprise value is 18.91 billion.

Market Cap	15.98B
Enterprise Value	18.91B

Important Dates

The last earnings date was Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

BL Pharmtech has 26.68 million shares outstanding. The number of shares has decreased by -0.43% in one year.

Current Share Class	26.68M
Shares Outstanding	26.68M
Shares Change (YoY)	-0.43%
Shares Change (QoQ)	+4.14%
Owned by Insiders (%)	27.53%
Owned by Institutions (%)	n/a
Float	19.33M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.29
PB Ratio	0.73
P/TBV Ratio	0.74
P/FCF Ratio	13.72
P/OCF Ratio	13.72
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.14
EV / Sales	2.71
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	16.24

Financial Position

The company has a current ratio of 0.60, with a Debt / Equity ratio of 0.24.

Current Ratio	0.60
Quick Ratio	0.32
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	4.42
Interest Coverage	-4.26

Financial Efficiency

Return on equity (ROE) is -24.23% and return on invested capital (ROIC) is -8.86%.

Return on Equity (ROE)	-24.23%
Return on Assets (ROA)	-7.44%
Return on Invested Capital (ROIC)	-8.86%
Return on Capital Employed (ROCE)	-18.78%
Revenue Per Employee	581.43M
Profits Per Employee	-501.55M
Employee Count	12
Asset Turnover	0.19
Inventory Turnover	2.46

Taxes

Income Tax	-131.89M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -4.92% in the last 52 weeks. The beta is 0.63, so BL Pharmtech's price volatility has been lower than the market average.

Beta (5Y)	0.63
52-Week Price Change	-4.92%
50-Day Moving Average	662.52
200-Day Moving Average	897.67
Relative Strength Index (RSI)	39.81
Average Volume (20 Days)	94,873

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BL Pharmtech had revenue of KRW 6.98 billion and -6.02 billion in losses. Loss per share was -225.93.

Revenue	6.98B
Gross Profit	4.00B
Operating Income	-4.33B
Pretax Income	-6.17B
Net Income	-6.02B
EBITDA	-3.64B
EBIT	-4.33B
Loss Per Share	-225.93

Full Income Statement

Balance Sheet

The company has 2.25 billion in cash and 5.15 billion in debt, giving a net cash position of -2.90 billion or -108.66 per share.

Cash & Cash Equivalents	2.25B
Total Debt	5.15B
Net Cash	-2.90B
Net Cash Per Share	-108.66
Equity (Book Value)	21.76B
Book Value Per Share	812.51
Working Capital	-3.90B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.16 billion and capital expenditures 10, giving a free cash flow of 1.16 billion.

Operating Cash Flow	1.16B
Capital Expenditures	10
Free Cash Flow	1.16B
FCF Per Share	43.65

Full Cash Flow Statement

Margins

Gross margin is 57.31%, with operating and profit margins of -62.05% and -86.26%.

Gross Margin	57.31%
Operating Margin	-62.05%
Pretax Margin	-88.43%
Profit Margin	-86.26%
EBITDA Margin	-52.16%
EBIT Margin	-62.05%
FCF Margin	16.69%

Dividends & Yields

BL Pharmtech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.43%
Shareholder Yield	0.43%
Earnings Yield	-37.66%
FCF Yield	7.29%

Stock Splits

The last stock split was on February 26, 2025. It was a forward split with a ratio of 3.

Last Split Date	Feb 26, 2025
Split Type	Forward
Split Ratio	3

Scores

BL Pharmtech has an Altman Z-Score of -2.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.73
Piotroski F-Score	3